It is an inhibitor for FKBP12 that entered Phase II clinical trials in the treatment of Parkinson’s disease where it showed marginal effects in compared to a placebo (NINDS NET-PD Investigators, 2007). This evidence concerns the gene FKBP1A and Parkinson disease.